טוען...
Complete response of advanced hepatocellular carcinoma to sorafenib: another case and a comprehensive review
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and...
שמור ב:
| הוצא לאור ב: | Clin Mol Hepatol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
The Korean Association for the Study of the Liver
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5760007/ https://ncbi.nlm.nih.gov/pubmed/28633200 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2016.0070 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|